PCM
KRON

Prelude Capital Management’s Kronos Bio KRON Stock Holding History

Prelude Capital Management’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-23,744
Closed -$34.7K – 1248
2023
Q1 		$34.7K Buy
23,744
+3,334
+16% +$6.39K ﹤0.01% 1026
2022
Q4 		$33.1K Buy
20,410
+2,300
+13% +$5.29K ﹤0.01% 1158
2022
Q3 		$61K Buy
+18,110
New +$81.7K ﹤0.01% 1217

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prelude Capital Management's KRON Position: Q2 2023 in Review

Prelude Capital Management sold out of Kronos Bio (KRON) in Q2 2023, closing a stake of 23,744 shares — an estimated $34.7K sold.

Prelude Capital Management first reported a position in KRON in Q3 2022 and held it in 3 quarters. The position peaked at $61K in Q3 2022. 80 funds tracked by Wall St. Rank hold KRON as of Q2 2023.

  • Prelude Capital Management reported no remaining Kronos Bio position as of Q2 2023 after selling out during the quarter.
  • Prelude Capital Management sold 23,744 Kronos Bio shares in Q2 2023, an estimated $34.7K.
  • Prelude Capital Management first reported a position in Kronos Bio in Q3 2022 and held it in 3 quarters.
  • Prelude Capital Management's Kronos Bio position peaked at $61K in Q3 2022.
  • 80 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2023.

Based on Prelude Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.